Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
2020 · New England Journal of Medicine · 6,783 citations
https://doi.org/10.1056/nejmoa1915745
A
Ahmed O. Kaseb
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
545
Papers
26.3K
Citations
67
h-index
183
i10-index
Ahmed O. Kaseb is an academic researcher from The University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Hepatocellular Carcinoma Treatment and Prognosis & Liver Disease Diagnosis and Treatment & Cancer Immunotherapy and Biomarkers. The author has an h-index of 67, co-authored 464 publications.
ORCID: 0000-0002-9491-0587Papers by this author
worksCamrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
2023 · The Lancet · 590 citations
https://doi.org/10.1016/s0140-6736(23)00961-3
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
2023 · The Lancet · 590 citations
https://doi.org/10.1016/s0140-6736(23)00961-3
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
2019 · JAMA Oncology · 460 citations
https://doi.org/10.1001/jamaoncol.2019.0270
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
2023 · The Lancet · 415 citations
https://doi.org/10.1016/s0140-6736(23)01796-8
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
2023 · The Lancet · 415 citations
https://doi.org/10.1016/s0140-6736(23)01796-8
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat